Cart is empty Patients with relapsed or refractory multiple myeloma who were treated with the two highest doses of REGN5459, a bispecific antibody targeting BCMA and CD3, experienced a 90.5% overall response rate, according to results of a phase I/II clinical trial presented at the AACR Annual Meeting 2023, held April 14-19.
Leave A Comment